Expression and function of hematopoiesis-stimulating factor receptors on the GPI− and GPI+ hematopoietic stem cells of patients with paroxysmal nocturnal hemoglobinuria/aplastic anemia syndrome

RONG FU†, SHAO-XUE DING†, YI LIU†, LI-JUAN LI, HUI LIU, HONG-LEI WANG, TIAN ZHANG and ZONG-HONG SHAO

Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China

Received October 13, 2014; Accepted September 28, 2015

DOI: 10.3892/etm.2016.3163

Abstract. Paroxysmal nocturnal hemoglobinuria/aplastic anemia (PNH/AA) syndrome presents a markedly increased population of cells deficient in glycoposphatidylinositol (GPI) cells and signs of bone marrow failure, which requires treatment with hematopoiesis-stimulating factors, such as granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). However, little is known about the effects of these stimulating factors on GPI cells. In order to explore the effects of stimulating factors in PNH/AA, G-CSF receptor (CD114) and SCF receptor (CD117) expression levels on GPI− and GPI+ hematopoietic stem cells (HSCs) were measured by flow cytometry (FCM). The mean fluorescence intensity (MFI) values of signal transducer and activator of transcription 5 (STAT5) and phosphorylated (P)-STAT5 were measured in GPI− and GPI+ HSCs by FCM following stimulation with G-CSF or SCF in vitro. The expression levels of CD114 and CD117 on GPI− HSCs were significantly lower (P<0.01) than those on GPI+ HSCs in PNH/AA patients and normal controls. The MFI values of STAT5 in the GPI− and GPI+ HSCs of PNH/AA patients and normal controls were not significantly different. However, the MFI values of P-STAT5 in the GPI HSCs of PNH/AA patients were significantly lower than those in the GPI+ HSCs of PNH/AA patients and normal controls prior to and following stimulation with G-CSF or SCF (P<0.01). The GPI HSCs of PNH/AA patients responded poorly to stimulation by hematopoiesis-stimulating factors, which indicates that these factors can be used safely in patients with PNH/AA.

Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic disorder arising from a mutation in the X chromosome-linked phosphatidylinositol glycan anchor biosynthesis, class A (PIGA), leading to a deficiency of proteins linked to the cell membrane via glycoposphatidylinositol (GPI) anchors. Abnormal and normal clones co-exist in the bone marrow of patients and the disease is characterized by bone marrow failure, intravascular hemolysis and thrombosis (1,2). The clinical association between PNH and aplastic anemia (AA) has long been recognized. PNH frequently occurs in association with suppressed hematopoiesis, including bone marrow failure syndrome. Hemolytic PNH can occur in the setting of AA, and conversely AA can be a late complication of PNH (3).

In a previous study, we confirmed that the expression levels of the erythropoietin receptor (EPOR) and thrombopoietin receptor (TPOR) on bone marrow (BM) GPI hematopoietic stem cells [HSCs; cluster of differentiation (CD)34+CD59−] in patients with PNH are significantly lower than those on the BM GPI+ HSCs (CD34+CD59+) in these patients (4). Furthermore, in vitro, following stimulation with erythropoietin (EPO) and thrombopoietin (TPO), the signal transducer and activator of transcription 5 (STAT5) phosphorylation levels of the EPOR and TPOR in the GPI+ clone of patients with PNH were clearly superior to those in the GPI− clone (5).

The aim of the present study was to further investigate the GPI HSC response to granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in PNH/AA syndrome. The expression of their respective receptors, CD114 and CD117, on GPI+ and GPI− HSCs were explored, and the mean fluorescence intensity (MFI) of the intracellular signaling pathway proteins STAT5 and phosphorylated (P)-STAT5 were measured before and after stimulation with G-CSF or SCF.

Materials and methods

Patients. A total of 23 patients with PNH/AA syndrome were enrolled in the study. These patients were hospitalized in the
Department of Hematology of Tianjin Medical University General Hospital (Tianjin, China) from March 2012 to May 2013 and diagnosed according to international criteria (6). Characteristics of the patients are listed in Table I. In addition, 15 healthy volunteers with a median age of 36 years (range, 22 to 65 years) were included as healthy controls. The study was approved by the Ethics Committee of Tianjin Medical University. Informed written consent was obtained from all patients or their parents in accordance with Declaration of Helsinki.

**Determination of CD114 and CD117 expression by flow cytometry (FCM).** Samples (2 ml) of fresh bone marrow (BM) were obtained from the patients and healthy controls. After filtration, 300 μl BM samples were divided into one control and two test tubes. An antibody against monoclonal mouse IgG1-PE (cat no. 555749; 1:5) was added as a negative control and the mouse monoclonal antibodies CD114-PE (cat no., 554538; 1:5) and CD117-PE (cat no., 340529; 1:5) were added to each test tube, respectively. Mouse monoclonal antibodies CD34-PerCP and CD59-FITC (cat no., 555763; 1:5) were stained in all tubes as markers of stem cells and the PNH clone. All antibodies were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Following incubation at 4°C for 30 min, red blood cells (RBCs) in the sample were lysed with 2 ml RBC lysing solution (BD Biosciences). Next, the bone marrow hematopoietic cells were washed twice with phosphate-buffered saline (PBS) and analyzed using a BD FACSCalibur flow cytometer (BD Biosciences) with CellQuest software, version 3.1. At least 100,000 cells were acquired for each sample.

**STAT5 and P-STAT5 analysis.** BM mononuclear cells (BMMNCs) were isolated by Ficoll-Hypaque density gradient centrifugation (750 g x for 5 min at 20°C; density, 1.077; Tianjin Hao Yang Biological Products Technology Co., Ltd., Tianjin, China). The samples were stimulated with BMMNCs (2-3x10^6 cells) G-CSF (100 ng/ml) or SCF (100 ng/ml) to induce the phosphorylation of STAT5 and fixed with crosslinking reagent (2% paraformaldehyde; Sigma-Aldrich, St. Louis, MO, USA). To stabilize the phosphorylation, the cells were fixed using 2% paraformaldehyde in PBS for 10 min at 4°C. The monoclonal antibodies CD34-PerCP and CD59-FITC were then added to the samples. After incubating at 4°C for 30 min, RBCs in the samples were lysed with 2 ml RBC lysing solution. The cells were mixed with 1.0 ml of FACS™ permeabilizing solution (BD Biosciences) for 10 min in the dark, and then incubated with STAT5-PE (cat no., 562077; 1:100 dilution) and p-STAT5-PE (cat no., 129010; 1:100 dilution) mouse monoclonal antibodies (BD Biosciences) at 4°C for 30 min. The cells were then washed twice with PBS. Information about ≥100,000 cells was acquired for each sample by FCM.

**Statistical analysis.** SPSS software, version 13.0 (SPSS, Inc., Chicago, IL, USA) was used. Measurement data are displayed as the mean ± standard deviation. Analysis of variance was used to evaluate differences between groups, followed by Student-Newman-Keuls test for multiple comparisons. A value of P<0.05 was considered statistically significant.

### Table I. Baseline characteristics of the patients.

| Patient no. | Age (years) | Gender | Disease phenotype | PNH clone (%) |
|-------------|-------------|--------|-------------------|--------------|
| 1           | 33          | F      | PNH/AA            | 31.2         |
| 2           | 24          | M      | PNH/AA            | 44.4         |
| 3           | 29          | F      | PNH/AA            | 41.4         |
| 4           | 77          | M      | PNH/AA            | 37.7         |
| 5           | 25          | M      | PNH/AA            | 39.6         |
| 6           | 72          | F      | PNH/AA            | 20.5         |
| 7           | 56          | F      | PNH/AA            | 45.3         |
| 8           | 40          | F      | PNH/AA            | 50.5         |
| 9           | 63          | F      | PNH/AA            | 26.8         |
| 10          | 28          | M      | PNH/AA            | 32.2         |
| 11          | 32          | M      | PNH/AA            | 49.7         |
| 12          | 60          | F      | PNH/AA            | 42.0         |
| 13          | 55          | F      | PNH/AA            | 37.9         |
| 14          | 30          | M      | PNH/AA            | 35.0         |
| 15          | 14          | F      | PNH/AA            | 32.1         |
| 16          | 39          | F      | PNH/AA            | 22.9         |
| 17          | 11          | M      | PNH/AA            | 47.8         |
| 18          | 42          | M      | PNH/AA            | 61.9         |
| 19          | 51          | F      | PNH/AA            | 29.8         |
| 20          | 36          | M      | PNH/AA            | 44.7         |
| 21          | 18          | F      | PNH/AA            | 31.0         |
| 22          | 44          | M      | PNH/AA            | 40.1         |
| 23          | 35          | M      | PNH/AA            | 28.4         |

F, female; M, male; PNH, paroxysmal nocturnal hemoglobinuria; AA, aplastic anemia.

### Results

**Expression of CD114 and C117 on GPI and GPI HSCs isolated from BM.** The expression levels of CD114 and CD117 on the GPI HSCs of patients with PNH/AA (44.23±19.77 and 49.20±26.80%, respectively) were significantly lower than those on the GPI HSCs of patients with PNH/AA (73.72±17.42 and 67.62±17.41%, respectively; P<0.01) or normal controls (65.91±13.70 and 70.21±12.68%, respectively; P<0.01). No significant difference was observed between the latter two groups (P>0.05; Fig. 1).

**Expression of STAT5 on GPI and GPI HSCs isolated from BM.** The MFI values for STAT5 on GPI and GPI HSCs of patients with PNH/AA (270.01±181.26, 205.05±146.16 and 227.39±156.65, respectively) were lower than those on the GPI HSCs of patients with PNH/AA (23 35 M PNH/AA 28.4... 67.62±17.41%, respectively; P<0.01). No significant difference was observed among the three groups (P>0.05; Fig. 2).

**Expression of P-STAT5 on GPI and GPI HSCs isolated from BM.** Prior to stimulation and following stimulation with G-CSF or SCF, the MFI values for P-STAT5 in the GPI HSCs of PNH/AA patients were 23.44±17.90, 35.73±33.93 and 33.19±26.45, respectively, which were significantly lower than

---

FU et al. HEMATOPOIESIS-STEMMING FACTOR RECEPTORS IN PNH/AA SYNDROME

---

**Table I. Baseline characteristics of the patients.**

| Patient no. | Age (years) | Gender | Disease phenotype | PNH clone (%) |
|-------------|-------------|--------|-------------------|--------------|
| 1           | 33          | F      | PNH/AA            | 31.2         |
| 2           | 24          | M      | PNH/AA            | 44.4         |
| 3           | 29          | F      | PNH/AA            | 41.4         |
| 4           | 77          | M      | PNH/AA            | 37.7         |
| 5           | 25          | M      | PNH/AA            | 39.6         |
| 6           | 72          | F      | PNH/AA            | 20.5         |
| 7           | 56          | F      | PNH/AA            | 45.3         |
| 8           | 40          | F      | PNH/AA            | 50.5         |
| 9           | 63          | F      | PNH/AA            | 26.8         |
| 10          | 28          | M      | PNH/AA            | 32.2         |
| 11          | 32          | M      | PNH/AA            | 49.7         |
| 12          | 60          | F      | PNH/AA            | 42.0         |
| 13          | 55          | F      | PNH/AA            | 37.9         |
| 14          | 30          | M      | PNH/AA            | 35.0         |
| 15          | 14          | F      | PNH/AA            | 32.1         |
| 16          | 39          | F      | PNH/AA            | 22.9         |
| 17          | 11          | M      | PNH/AA            | 47.8         |
| 18          | 42          | M      | PNH/AA            | 61.9         |
| 19          | 51          | F      | PNH/AA            | 29.8         |
| 20          | 36          | M      | PNH/AA            | 44.7         |
| 21          | 18          | F      | PNH/AA            | 31.0         |
| 22          | 44          | M      | PNH/AA            | 40.1         |
| 23          | 35          | M      | PNH/AA            | 28.4         |

F, female; M, male; PNH, paroxysmal nocturnal hemoglobinuria; AA, aplastic anemia.
those in the GPI- HSCs of PNH/AA patients (63.42±47.63, 123.45±80.40 and 123.41±93.40, respectively; P<0.01) or normal controls (61.30±32.13, 116.00±56.52 and 126.86±60.20, respectively; P<0.01). No statistically significant difference was identified in the P‑STAT5 MFI values between the latter two groups (P>0.05; Fig. 3).

**Discussion**

PNH is an acquired clonal disease characterized by complement-mediated hemolysis, bone marrow failure and thrombosis. Some patients present with markedly increased levels of GPI- HSCs and signs of bone marrow failure, which lead to a diagnosis of PNH/AA syndrome (7). The conventional methods for the treatment of PNH/AA syndrome include glucocorticoids, androgens, cyclosporine, anti-T-lymphocyte globulin (ATG) and hemopoietic stem cell transplantation (8-10). A new targeted and disease-modifying treatment strategy is the inhibition of the terminal complement cascade with the humanized monoclonal anti-C5 antibody, eculizumab, which can effectively control hemolysis and thrombosis (11-13). Economic reasons cause many patients with PNH/AA syndrome to undergo immunosuppressive treatment and treatment with hemopoietic stimulating factors, such as G-CSF and EPO. However, at present, little is known about the effects of these hemopoietic stimulating factors on GPI- HSCs. It has been demonstrated that adding EPO and TPO to chemotherapy may promote the proliferation and differentiation of normal clone cells, and eliminate the abnormal PNH clone fundamentally (4,5). In the present study, the aim was to explore the effects of G-CSF and SCF in PNH/AA syndrome.

The cytokine G-CSF promotes the proliferation, differentiation, survival and functional maturation of cells within the neutrophil granulocyte lineage (14). Its cell-surface receptor (G-CSFR; CD114) plays an important role in the production, survival and activation of neutrophilic granulocytes during normal and emergency hematopoiesis (14). This has led to...
several important clinical applications for its ligand, G-CSF, which binds to the G-CSFR causing activation via homodimerization and subsequent phosphorylation on four tyrosine residues of the receptor intracellular domain (15). This initiates a range of intracellular signaling events including the activation of Janus kinase (JAK)/STAT pathways (15,16). Ward et al (17) further highlighted the importance of STAT5 in the mediation of proliferative responses to G-CSF after studying the association between STAT5 and severe congenital neutropenia.

SCF is a critical cytokine during hematopoiesis, which regulates stem and progenitor cell survival and proliferation. The receptor for SCF, c-Kit (CD117), is a member of the tyrosine kinase family of receptors and undergoes autophosphorylation upon binding with SCF, resulting in the activation of multiple signaling proteins such as JAK/STAT, phosphoinositide 3-kinase, Src kinases, Shc and Ras (18,19). Brizzi et al (20) found that STAT1α, STAT5A and STAT5B participate in the signaling transduction of SCF.

In the present study, the expression levels of CD114 and CD117 on HSCs from the BM of PNH/AA patients were detected, and it was found that the expression levels on GPI− HSCs were significantly lower than those on the GPI+ HSCs of PNH/AA patients or normal controls. Therefore, this characteristic can be utilized in the treatment of PNH/AA to promote the proliferation of the normal clone instead of the PNH clone. In order to further investigate the functions of CD114 and CD117, the signaling pathway protein STAT5 was measured in the HSCs by FCM. No significant difference in the STAT5 MFI was observed among the three groups, that is, among the GPI− and GPI+ HSCs of patients with PNH/AA and the GPI+ HSCs of normal controls. This indicates that there were no abnormal quantities of intracellular pathway proteins among the three groups. Furthermore, the expression levels of P-STAT5 were measured in the BMMNCs of PNH/AA patients and normal controls prior to and following stimulation with G-CSF or SCF in vitro. It was found that the MFI of P-STAT5 in the unstimulated or G-CSF- or SCF-stimulated PNH (GPI+) clone cells was lower than that in normal clone cells, and no significant difference was observed between the GPI+ HSCs of the PNH patients and normal controls. This indicates that G-CSF or SCF can significantly increase the proliferation and differentiation of normal clones, while having little effect on abnormal PNH clones. In a previous study (21), it was found that in vitro, the BMMNCs of normal controls had better proliferative capacity and gave a stronger response to G-CSF than those of patients with PNH, which is consistent with the results of the present study. The present study also found that the expression level of P-STAT5 in PNH clone cells was lower than that in normal clone cells prior to stimulation with G-CSF or SCF. However, normal clone cells did not acquire a proliferative advantage. By contrast, PNH clone cells were amplified, which would eventually lead to a series of clinical manifestations. This may be due to a complex mechanism, leading to PNH clones evading immune attacks,
undergoing a reduction in apoptosis decrease and gaining a proliferative advantage (22,23). Through the application of hematopoiesis-stimulating factors in PNH/AA patients, the degree of phosphorylation of normal clone cells can be significantly increased, which may overcome the various factors that lead to proliferation of the abnormal clone, leading to gradual proliferation of the normal clone and the restoration of normal hematopoiesis.

In conclusion, PNH clone cells responded poorly to stimulation by the hematopoiesis-stimulating factors G-CSF and SCF. The findings of the present study may facilitate the deeper development of hematopoiesis-stimulating factors in PNH/AA patients. However, further studies are required in order to investigate the mechanism in more detail.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grants nos. 30971285, 30971286 and 81170472), Tianjin Municipal Natural Science Foundation (grant nos. 14JCZDJC25400 and 12JZDJC21500), Tianjin Medical University Foundation (grant nos. 2011k07 and 2010ky20), Science and Technology Foundation of Tianjin Municipal Health Bureau (grant nos. 2011kz115 and 2010ky105), Tianjin Municipal Health Industry Key Project (grant no. 11KG135) and Tianjin Municipal Anticancer Major Project (grant nos. 12ZZDSY18000 and 12ZCDZSY17900).

References

1. de Latour RP, Mary JY, Salanoubat C, Terziou L, Etienne G, Mohy M, Roth S, de Guibert S, Maury S, Cahn JY and Socié G; French Society of Hematology; French Association of Young Hematologists: Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories. Blood 112: 3099-3106, 2008.
2. Pefaulle de Latour R, Amoura Z and Socié G: Paroxysmal nocturnal hemoglobinuria. Rev Med Interne 31: 200-207, 2010 (In French).
3. Kinoshita T and Inoue N: Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria. Int J Hematol 75: 117-122, 2002.
4. Wang D, Fu R, Ruan EB, Qu W, Liang Y, Wang HQ, Wang J, Li LJ, Liu H, Wang HL, et al: EPOR and TPOR expressions on CD34+ CD59- bone marrow cells from patients with paroxysmal nocturnal hemoglobinuria. Zhonghua Xue Ye Xue Za Zhi 32: 543-547, 2011 (In Chinese).
5. Wang D, Fu R, Ruan EB, Qu W, Liang Y, Wang HQ, Wang J, Li LJ, Liu H, Wang HL, et al: STAT5 phosphorylation levels of erythropoietin and thrombopoietin receptors in CD34+CD59- and CD34+CD59+ bone marrow cells of patients with paroxysmal nocturnal hemoglobinuria. Zhonghua Yi Xue Za Zhi 91: 2129-2135, 2011 (In Chinese).
6. Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT and Richards SJ: Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 78: 211-230, 2010.
7. Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA and Illingworth A: A prospective multicenter study of paroxysmal nocturnal hemoglobinuria patients in cells with bone marrow failure. Cytometry B Clin Cytom 86: 175-182, 2014.
8. Arruda MM, Rodrigues CA, Yamamoto M and Figueiredo MS: Paroxysmal nocturnal hemoglobinuria: From pathological process to treatment. Rev Assoc Med Bras 56: 214-221, 2010 (In Portuguese).
9. Brodsky RA: How I treat paroxysmal nocturnal hemoglobinuria. Blood 113: 6522-6527, 2009.
10. Raitola AM, VanLint MT, Lamparelli T, Gualandi F, Benvenuto F, Figari O, Mordini N, Berissi G, Bregante S, Frassoni F and Baccigalupo A: Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica 85: 59-62, 2000.
11. Röth A and Dührsen U: Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Eur J Haematol 87: 473-479, 2011.
12. Charneski L and Patel PN: Eculizumab in paroxysmal nocturnal haemoglobinuria. Drugs 68: 1341-1346, 2008.
13. Linderfor MA, Pawluczkwycz AW, Peek EM, Hickman K, Taylor RP and Parker CF: A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: Both complement-mediated cytosis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115: 2283-2291, 2010.
14. Scholz M, Schirm S, Wetzel M, Engel C and Loeffler M: Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. Theor Biol Med Model 9: 32, 2012.
15. Liangue C, Wright C, Russell AP and Ward AC: Granulocyte colony-stimulating factor receptor: Stimulating granulopoiesis and much more. Int J Biochem Cell Biol 41: 2372-2375, 2009.
16. Marino VJ and Roguin LP: The granulocyte colony stimulating factor (G-CSF) activates Jak/STAT and MAPK pathways in a trophoblastic cell line. J Cell Biochem 103: 1512-1523, 2008.
17. Ward AC, Gits J, Majeed F, Aprikyan AA, Lewis RS, O'Sullivan LA, Freedman M, Shigdar S, Touw IP, Dale DC and Dror Y: Functional interaction between mutations in the granulocyte colony-stimulating factor receptor in severe congenital neutropenia. Br J Haematol 142: 653-656, 2008.
18. Roskoski R Jr: Structure and regulation of Kit protein-tyrosine kinase - The stem cell factor receptor. Biochem Biophys Res Commun 338: 1307-1315, 2005.
19. Zhang Z, Zhang R, Joachimiak A, Schlessinger J and Kong XP: Crystal structure of human stem cell factor: Implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci USA 97: 7732-7737, 2000.
20. Brizzi MF, Dentelli P, Rosso A, Yarden Y and Pogaroro L: STAT protein recruitment and activation in c-Kit deletion mutants. J Biol Chem 274: 16965-16972, 1999.
21. Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, et al: The role of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients. Zhonghua Xue Ye Xue Za Zhi 26: 235-238, 2005 (In Chinese).
22. Savage WJ, Barber JP, Mukhina GL, Hu R, Chen G, Matsui W, Thoburn C, Hess AD, Cheng L, Jones RJ and Brodsky RA: Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol 37: 42-51, 2009.
23. Cao YR, Shao ZH, Liu H, Zhao MF, He GS, Shi J, Bai J, Fu R, Tu MF, Wang HQ, et al: Expression of apoptosis-related proteins in bone marrow neutrophils of patients with paroxysmal nocturnal hemoglobinuria. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13: 871-874, 2005 (In Chinese).